Susmed

Susmed EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Susmed (4263.T) as of Oct 30, 2026 is -23.18. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -27.51 — a change of -15.73% (higher).

EV/FCF

-23.18

YoY

-15.73%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Susmed is 2026 -23.18 . EV/FCF (Enterprise Value to Free Cash Flow) of Susmed was 2025 -27.51 . It decreases by -15.73% higher compared to the previous year.

The Susmed EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2020
-172.00 JPY
Jan 1, 2021
-61.37 JPY
Jan 1, 2022
-64.69 JPY
Jan 1, 2023
137.91 JPY
Jan 1, 2024
-48.18 JPY
Jan 1, 2025
-27.51 JPY
Jan 1, 2026
-23.18 JPY
The Susmed EV/FCF history
YEAREV/FCFYoY
-23.18-15.73%
-27.51-42.91%
-48.18-134.94%
137.91-313.17%
-64.69+5.41%
-61.37-64.32%
-172.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

EV/FCF (Enterprise Value to Free Cash Flow) of Susmed is -23.18 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Susmed changed from -27.51 to -23.18, representing a -15.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Susmed since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Susmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Susmed

All Key Metrics — Susmed